FERRARO, Diana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.820
AS - Asia 5.465
EU - Europa 5.123
SA - Sud America 984
AF - Africa 144
OC - Oceania 51
Continente sconosciuto - Info sul continente non disponibili 3
Totale 26.590
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.579
GB - Regno Unito 1.728
SG - Singapore 1.616
CN - Cina 1.245
IT - Italia 850
VN - Vietnam 774
BR - Brasile 734
HK - Hong Kong 727
DE - Germania 479
SE - Svezia 410
FI - Finlandia 389
BD - Bangladesh 279
RU - Federazione Russa 242
FR - Francia 241
UA - Ucraina 200
TR - Turchia 133
BG - Bulgaria 129
CA - Canada 122
IN - India 116
KR - Corea 112
ID - Indonesia 94
AR - Argentina 93
MX - Messico 73
ES - Italia 64
NL - Olanda 57
CZ - Repubblica Ceca 51
AU - Australia 50
IQ - Iraq 49
PL - Polonia 49
JP - Giappone 48
AT - Austria 43
ZA - Sudafrica 42
EC - Ecuador 39
AE - Emirati Arabi Uniti 35
IE - Irlanda 34
CL - Cile 30
PK - Pakistan 29
IR - Iran 27
MY - Malesia 27
BE - Belgio 25
DK - Danimarca 25
CH - Svizzera 24
CO - Colombia 22
VE - Venezuela 22
MA - Marocco 20
PH - Filippine 20
EG - Egitto 19
PY - Paraguay 17
KE - Kenya 16
LT - Lituania 16
TN - Tunisia 16
JO - Giordania 14
TW - Taiwan 12
PE - Perù 11
SA - Arabia Saudita 11
UY - Uruguay 11
BZ - Belize 10
GE - Georgia 10
UZ - Uzbekistan 10
AZ - Azerbaigian 8
NP - Nepal 8
PT - Portogallo 8
DO - Repubblica Dominicana 7
IL - Israele 7
DZ - Algeria 6
GR - Grecia 6
JM - Giamaica 6
OM - Oman 6
QA - Qatar 6
RO - Romania 6
AL - Albania 5
HU - Ungheria 5
KZ - Kazakistan 5
LB - Libano 5
NO - Norvegia 5
RS - Serbia 5
SI - Slovenia 5
TH - Thailandia 5
BB - Barbados 4
BO - Bolivia 4
CR - Costa Rica 4
PA - Panama 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
ET - Etiopia 3
GA - Gabon 3
HN - Honduras 3
HR - Croazia 3
KW - Kuwait 3
LK - Sri Lanka 3
NG - Nigeria 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AO - Angola 2
BN - Brunei Darussalam 2
EE - Estonia 2
EU - Europa 2
GT - Guatemala 2
Totale 26.551
Salva come PNG Salva come JPEG
Città #
Fairfield 1.819
Ashburn 1.458
Santa Clara 1.380
Southend 1.203
Singapore 952
Woodbridge 872
Hong Kong 715
Seattle 712
Houston 701
Chandler 624
Cambridge 605
Wilmington 551
San Jose 422
Ann Arbor 354
Helsinki 326
Dearborn 317
London 300
Chicago 297
Jacksonville 292
Nyköping 284
Ho Chi Minh City 252
Los Angeles 229
Beijing 219
New York 214
Council Bluffs 213
Hanoi 183
Modena 175
Hefei 165
The Dalles 152
San Diego 143
Munich 135
Sofia 122
Princeton 120
Salt Lake City 109
Moscow 86
Shanghai 86
Buffalo 81
Seoul 81
Milan 79
Lauterbourg 78
Eugene 73
Dallas 68
Jakarta 66
São Paulo 62
Frankfurt am Main 54
Tampa 51
Elk Grove Village 50
Bremen 47
Orem 45
Izmir 44
Rome 44
Redwood City 42
Phoenix 41
Norwalk 39
Da Nang 38
Toronto 37
Warsaw 35
Boardman 34
Columbus 34
Rio de Janeiro 32
Miami 30
Málaga 30
Redondo Beach 30
Brno 29
Manchester 29
Tokyo 29
Dublin 28
Guangzhou 28
Sterling 28
Turku 28
Vienna 27
Haiphong 26
Amsterdam 25
Fremont 25
Lancaster 24
Melbourne 24
Chennai 23
Seongnam 23
Stockholm 23
Dulles 22
Hillsboro 22
Johannesburg 22
Kunming 22
Baghdad 21
Atlanta 20
Boston 20
Miano 20
Nuremberg 20
Washington 20
Brooklyn 18
Buenos Aires 18
Edinburgh 18
Falls Church 18
Paris 18
Brussels 17
Copenhagen 17
Mexico City 17
Montreal 17
Piacenza 17
Vancouver 16
Totale 18.951
Salva come PNG Salva come JPEG
Nome #
Definitive childlessness in women with multiple sclerosis: a multicenter study 677
Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome. 452
Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis 448
A quantitative comparison of BOLD fMRI responses to noxious and innocuous stimuli in the human spinal cord 397
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study 394
Isolated progressive cognitive impairment and depression in a patient with neuroradiological features suggestive of multiple sclerosis 393
Aging with HIV infection: a journey to the center of inflammAIDS, immunosenescence and neuroHIV 393
Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient 387
Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study 371
iNKT cells in secondary progressive multiple sclerosis patients display pro-inflammatory profiles 369
A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band 368
False positive absent somatosensory evoked potentials in cardiac arrest with therapeutic hypothermia. 363
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: Results from an observational study 363
Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis 361
First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence 358
Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study 339
Paroxysmal ventricular tachicardia and pure right insular stroke 338
Changing incidence and subtypes of ALS in Modena, Italy: A 10-years prospective study 336
Acute hemichorea as unusual first multiple sclerosis presentation 333
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 326
Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome 325
Mitochondrial damage-associated molecular patterns stimulate reactive oxygen species production in human microglia 322
Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients 320
Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study 317
Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis 313
Methylprednisolone-induced toxic hepatitis after intravenous pulsed therapy for multiple sclerosis relapses 306
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 305
Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band‐negative patients with suspected multiple sclerosis 296
Inter-center agreement in the interpretation of oligoclonal bands 289
Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM 288
TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis 278
Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis 278
Semiautomated segmentation of the human spine based on echoplanar images 278
Antiepileptic drugs in the treatment of headache: Neuroprotective effect or something else? 275
Severe anemia in a patient with multiple sclerosis treated with natalizumab 267
Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis 267
Acute necrotizing encephalopathy: A relapsing case in a European adult [4] 262
Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect? 262
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS 257
Diagnostics of dysimmune peripheral neuropathies 256
Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine 255
Systematic assessment and characterization of chronic pain in multiple sclerosis patients 252
Diagnostics of anti-MAG antibody polyneuropathy 251
Abnormal Circadian Modification of Aδ-Fiber Pathway Excitability in Idiopathic Restless Legs Syndrome 249
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis 247
Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients 246
Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor? 245
Topiramate in migraine prophylaxis: A randomised double-blind versus placebo study 244
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis 243
Charcot-Marie-Tooth and pain: Correlations with neurophysiological, clinical, and disability findings 241
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis 240
Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis 239
The abnormal recovery cycle of somatosensory evoked potential components in children with migraine can be reversed by topiramate 235
Habituation to Pain in "Medication Overuse Headache": A CO2 Laser-Evoked Potential Study 233
Antiepileptic drugs in the preventive treatment of migraine in children and adolescents 233
Mechanisms of neuropathic pain in patients with Charcot-Marie-Tooth 1 A: A laser-evoked potential study 232
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study) 229
The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study 224
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: Acetylcholinesterase activity cannot be considered a useful biomarker 217
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy 217
Detection of Neurofilament Light Chain with Label-Free Electrolyte-Gated Organic Field-Effect Transistors 217
Topiramate in the prevention of pediatric migraine: Literature review 215
Left thalamomegaly in a patient with partial epilepsy 214
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study 213
Letter to Editor: Carpal tunnel syndrome due to an atypical deep soft tissue leiomyoma: The risk of misdiagnosis and mismanagement 212
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study 211
Multiple attack study on the available triptans in Italy versus placebo 209
Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients 207
Evidence of different spinal pathways for the warmth evoked potentials 207
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis 207
Kappa Index Versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders 201
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy 200
Acute hemichorea as unusual first multiple sclerosis presentation: two case reports 198
A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis 194
Antiepileptic drugs in migraine prophylaxis: state of the art 193
Treatment response score to glatiramer acetate or interferon beta-1a 186
Informing MS patients on treatment options: a consensus on the process of consent taking 185
Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing–remitting multiple sclerosis 184
Occupational head injury and subsequent glioma 182
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis 182
Cell-based assays for the detection of MOG antibodies: a comparative study 182
Risk of secondary progressive multiple sclerosis: A longitudinal study 178
A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia 177
Modulation of tregs and inkt by fingolimod in multiple sclerosis patients 173
Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients 172
Conversion to secondary progressive multiple sclerosis: Patient awareness and needs. Results from an online survey in Italy and Germany 167
Diagnostic features of initial demyelinating events associated with serum MOG-IgG 167
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years 165
Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus 160
Association of Sustained Immunotherapy with Disability Outcomes in Patients with Active Secondary Progressive Multiple Sclerosis 156
A novel SOD1 mutation in a young ALS patient associated with slowly progressive clinical course 156
Microglia activation: A role for mitochondrial DNA? 151
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder 149
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 134
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 134
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 132
A study of the CD45 exon 4 C77G polymorphism in a patient affected both by multiple sclerosis and pulmonary Langerhans' cell histiocytosis 132
Early clinical markers of aggressive multiple sclerosis 128
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies 126
Efficacy of mechanical thrombectomy in patients with ischemic stroke and cancer 125
Totale 25.380
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.434
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.434
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021140 0 0 0 0 0 0 0 0 0 0 0 140
2021/20222.370 216 274 249 93 40 134 107 141 252 225 403 236
2022/20231.749 198 206 146 181 198 250 21 191 193 13 102 50
2023/20241.247 33 77 60 158 229 108 147 155 30 15 63 172
2024/20254.290 151 37 47 322 911 713 198 213 499 242 382 575
2025/20268.837 525 336 704 1.013 1.399 673 967 476 842 727 681 494
Totale 26.797